Company Name: J-Pharma Co., Ltd.
Name of Representative: President and CEO, Masuhiro Yoshitake
Securities Code: 520A Tokyo Stock Exchange Growth Market
October 7, 2026
J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; hereinafter “J-Pharma” or the “Company”) today announced that President and CEO Masuhiro Yoshitake spoke at a luncheon seminar hosted by Syneos Health Japan during BioJapan 2026, held at PACIFICO Yokohama on October 7, 2026.
Presentation and Venue Scenes from the BioJapan 2026 Luncheon Seminar.
The seminar, titled “Real-World Lessons in Global Clinical Development and Market Expansion,” featured presentations and discussions on global clinical development strategies and overseas market expansion. Drawing on J-Pharma’s experience in global development and its initial public offering (IPO), Yoshitake discussed the company’s efforts and the challenges faced by Japanese biotech companies pursuing international expansion.
J-Pharma will continue working with partners in Japan and overseas to bring innovative medicines developed in Japan to patients worldwide.
■ Seminar Overview
Seminar Title: Real-World Lessons in Global Clinical Development and Market Expansion
Date and time: October 7, 2026, 12:00–13:00 (JST)
Venue: F201, PACIFICO Yokohama
Host: Syneos Health Japan
J-Pharma speaker: Masuhiro Yoshitake, President and CEO
■ Related Information
- –BioJapan 2026 Official Website
- –Notice of Listing on the Tokyo Stock Exchange Growth Market (2026.03.25)
- –Interview with President Masuhiro Yoshitake
Net-Presentations Kitai Shihon
B-side Leaders (May 20, 2026)
https://www.youtube.com/watch?v=xfwR-QdjYPc - –Matters Relating to Business Plans and Growth Potential (2026.06.26)
About J-Pharma Co., Ltd.
J-Pharma Co., Ltd. aims to pursue new possibilities for SLC transporters and contribute to the hope and health of people worldwide through the development of innovative new drugs that address unmet medical needs. Under this mission, the Company has focused on LAT1 (L-type amino acid transporter 1), one of the SLC transporters discovered by the Company’s founder, and is advancing the development of LAT1 inhibitors to address the needs of patients with cancer and autoimmune diseases, where existing drugs are insufficient.
For more information, please visit:
https://www.j-pharma.com/en/
Inquiries:
J-Pharma Co., Ltd.
Planning Department
TEL: +81-3-6432-4270
https://www.j-pharma.com/en/contact